A glycodendrimer comprising: a) a non-toxic dendrimer polypropyletherimine core supporting on average in the range of 9 to 64 terminal carboxylic acid groups, and b) conjungated to said core in the range of 2 to 8 amino sugars or a sulphate amino sugars selected from the group consisting of glucosamine, N-acetyl glucosamine, mannosamine, N-acetylmannosamine, galactosamine, a sulphate of any one of the same and a combination thereof, wherein each sugar is linked directly through a zero length amide bond with a residue of a terminal carboxylic acid group. The invention also extended to defined populations comprising said glycodendrimer molecules, pharmaceutical compositions comprising said molecules or populations, process for preparing the molecules and formulations, and therapeutic uses of the molecules, populations and compositions.
